Global environmental changes have been associated with rising rates of skin infections such as cellulitis, driven in part by increased exposure and microbial shifts. Cellulitis is most commonly caused by Staphylococcus aureus and Streptococcus species and is clinically challenging because of recurrence, antimicrobial resistance, and the limitations of systemic antibiotic therapies. Oral antibiotics such as Ofloxacin can be effective systemically but are limited by suboptimal local drug concentrations and systemic adverse effects. The authors designed a local, dual-action delivery system to improve drug localization, provide sustained antimicrobial exposure, and offer immediate pain relief at the lesion site.
Ofloxacin was encapsulated in polymeric nanoparticles using Eudragit S100 as the matrix polymer and the nanoprecipitation technique as the preparation method. The nanoparticle formulation was optimized using a Design of Experiments approach. Optimization targeted high drug entrapment and nanoscale particle size to improve penetration and retention in the dermal environment. The optimized nanoparticles achieved an entrapment efficiency of approximately 96% and particle sizes in the 85–110 nm range as reported in the abstract.
The nanoparticle dispersion was incorporated into a mucoadhesive in situ gel composed of Carbopol and HPMC. Lidocaine was included in the gel matrix to confer immediate local analgesic effect upon application. The composite system was engineered to be pH-responsive, undergoing a sol-to-gel transition in response to the local wound pH. Under simulated wound conditions, the formulation exhibited increased viscosity consistent with gelation and improved retention at the application site.
Characterization reported in the abstract highlights nanoscale particle size and high drug entrapment. The integrated system demonstrated sustained drug release following controlled kinetics. Release behavior was pH-triggered by the polymer selection and gel environment, providing prolonged Ofloxacin availability at the local site. The gel showed enhanced viscosity under simulated wound pH, supporting localized residence time and controlled liberation of drug from the nanoparticulate carrier embedded in the gel matrix.
According to the abstract, in vitro and ex vivo studies evaluated permeation, post-permeation drug release, and antimicrobial efficacy. The system produced prolonged drug release after permeation and improved retention compared with non-optimized controls. Antimicrobial activity was confirmed by standard microbiological metrics, specifically MIC and MBC testing, indicating effective bactericidal/bacteriostatic performance of the released Ofloxacin against relevant pathogens in the study.
The formulation was evaluated in vivo using Staphylococcus aureus–infected rat models. Treated animals demonstrated reduced lesion severity and accelerated healing. The abstract reports absence of skin irritation and inflammation attributable to the formulation, suggesting local tolerability in the preclinical model. These in vivo results align with the intended benefits of localized, sustained antimicrobial delivery coupled with immediate analgesia via lidocaine.
This dual-delivery platform combines a pH-responsive in situ gel with Ofloxacin-loaded nanoparticles and lidocaine to address several limitations of systemic therapy for cellulitis: improved local drug concentration and retention, sustained antimicrobial exposure to counter recurrence and resistance-related failures, and immediate symptom relief to improve patient comfort and potentially adherence. The design leverages pH changes in wound environments to trigger gelation and modulate release, which may enhance site-specific performance compared with non-responsive formulations.
The PubMed abstract provides key formulation features and summary outcomes but does not include full experimental details, such as exact concentrations, complete kinetic parameters, quantitative comparative statistics across controls, sample sizes, or detailed safety/toxicity endpoints beyond the statements of no irritation and accelerated healing in the animal model. For full methodological details, raw data, and statistical analyses, readers should consult the full text of the published article.
Overall, the described preclinical data support further development of a pH-responsive, nanoparticle-loaded in situ gel combining sustained Ofloxacin delivery and local analgesia for management of cellulitis, with promising efficacy and tolerability in early models.